Abcam (LON:ABC)‘s stock had its “neutral” rating reaffirmed by stock analysts at JPMorgan Chase & Co. in a note issued to investors on Monday. They currently have a GBX 946 ($12.83) price objective on the stock. JPMorgan Chase & Co.’s price objective indicates a potential downside of 16.80% from the company’s current price.
A number of other research analysts have also weighed in on the company. Numis Securities lifted their target price on Abcam from GBX 1,116 ($15.13) to GBX 1,200 ($16.27) and gave the company an “add” rating in a report on Tuesday, September 12th. Panmure Gordon reaffirmed a “sell” rating on shares of Abcam in a report on Monday, September 11th. Berenberg Bank reaffirmed a “buy” rating and set a GBX 1,100 ($14.92) target price on shares of Abcam in a report on Monday, September 11th. Finally, Peel Hunt reaffirmed a “hold” rating and set a GBX 1,020 ($13.83) target price on shares of Abcam in a report on Wednesday, November 29th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company. Abcam has a consensus rating of “Hold” and a consensus price target of GBX 996 ($13.51).
Abcam (ABC) opened at GBX 1,137 ($15.42) on Monday. The firm has a market capitalization of $2,330.00 and a PE ratio of 5,414.29. Abcam has a twelve month low of GBX 9.73 ($0.13) and a twelve month high of GBX 1,156 ($15.68).
Abcam plc is a global life sciences company. As a developer of reagents and tools, the Company’s purpose is to serve life science researchers globally. Providing the research and clinical communities with tools and scientific support, the Company offers validated biological binders and assays to address important targets in critical biological pathways.
What are top analysts saying about Abcam? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Abcam and related companies.